Can Promoter Methylation Serve as a Biomarker for Cancer?
Yes, promoter methylation patterns can serve as valuable biomarkers for cancer diagnosis, prognosis, and therapeutic response. For example, the hypermethylation of specific genes in circulating tumor DNA (ctDNA) can be detected in blood samples, providing a non-invasive method for early cancer detection and monitoring. Furthermore, the methylation status of certain genes can predict how well a patient will respond to particular treatments.
